TheEdgeResearch
Home / Stocks / BRIBF

Brii Biosciences Limited (BRIBF)

OTC Healthcare Biotechnology
$0.13 ▲ +0.00%
Market Cap
$93.4M
Sector
Healthcare
Industry
Biotechnology
Beta
1.20
52-Wk Range
0.12575-0.2459
CEO
Zhi Hong
Country
CN
Currency
USD

Brii Biosciences Limited operates in the Biotechnology industry of the Healthcare sector, headquartered in Beijing, BE, CN. The stock last traded at $0.13, up 0.00% on the session, giving a market capitalisation of $93.4M. On trailing twelve-month figures it carries a trailing P/E of -3.55, a net margin of -918.1%. Its beta of 1.20 implies it has historically moved more than the broad market.

Valuation & profitability (TTM)
P/E
-3.55
Price / Sales
33.30
Price / Book
0.28
EV / EBITDA
-0.42
Gross margin
63.1%
Operating margin
-1478.3%
Net margin
-918.1%
Return on equity
—
Debt / equity
0.00
Current ratio
52.24
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
75
IPO date
2022-01-21
Headquarters
Beijing, BE, CN
About Brii Biosciences Limited

Founded in Beijing, China, in 2017, Brii Biosciences Limited is a biopharmaceutical firm dedicated to discovering and developing innovative therapies for infectious diseases and central nervous system disorders. Its diverse pipeline features: early-stage (Phase 1) compounds BRII-778 and BRII-732 for treating HIV; a multifaceted approach to Hepatitis B (HBV) including a Phase 2 combination study of BRII-179 and BRII-835, with BRII-179 (a recombinant protein-based immunotherapeutic) also in Phase 1b/2a, and BRII-835 having successfully completed Phase 2 for chronic HBV patients. The company also offers the Amubarvimab/romlusevimab combination as a treatment for COVID-19. Beyond these, Brii Biosciences is advancing BRII-296 for PPD and BRII-297 for various depressive conditions, alongside several agents targeting highly resistant infections: BRII-636, BRII-672, and BRII-693 are designed to combat multi-drug and extensively drug-resistant (MDR/XDR) gram-negative bacteria, while BRII-658 is under development for MDR/XDR tuberculosis and non-tuberculosis mycobacterial infections.

Comparable companies

Brii Biosciences Limited is most often compared with the following Healthcare names:

BCCOYBXPHFCLLKFGNFTFIPHYFJWCTFMLLCFNDTPNGENFSCNLF
More research on BRIBF
BRIBF technical analysis BRIBF TheEdge Score Compare against peers
Open full interactive analysis & DCF →